<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936867</url>
  </required_header>
  <id_info>
    <org_study_id>CARYSMA Registry Study 466/16</org_study_id>
    <nct_id>NCT04936867</nct_id>
  </id_info>
  <brief_title>The CArdiac Imaging RegistrY Study</brief_title>
  <acronym>CARYSMA</acronym>
  <official_title>The CArdiac Imaging RegistrY Study: Computed ToMogrAphy for Risk Stratification and Diagnostic Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective longitudinal observational investigator-led single centre cohort study we&#xD;
      will include patients undergoing cardio-CT for clinical reasons, to evaluate the role of&#xD;
      cardio-CT terms of its diagnostic and prognostic value, as well as risk-benefit ratio.&#xD;
&#xD;
      Particular aims include:&#xD;
&#xD;
        1. To determine the prevalence of CAD for age, gender, ethnicity relative to established&#xD;
           risk models&#xD;
&#xD;
        2. To determine associations between CAD severity and plaque type and:&#xD;
&#xD;
             1. with traditional risk factors (arterial hypertension, diabetes,&#xD;
                hypercholesterolemia, smoking)&#xD;
&#xD;
             2. blood markers of increased cardiovascular risk&#xD;
&#xD;
        3. To determine predictive associations of between CAD with outcome (endpoint definitions&#xD;
           in appendix)&#xD;
&#xD;
        4. To determine the risk-benefit ratio (number of subsequent interventions, complications,&#xD;
           radiation exposure, late onset of cancer diseases, etc).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Particular aims include:&#xD;
&#xD;
        1. To determine the prevalence of CAD for age, gender, ethnicity relative to established&#xD;
           risk models&#xD;
&#xD;
        2. To determine associations between CAD severity and plaque type and:&#xD;
&#xD;
             1. with traditional risk factors (arterial hypertension, diabetes,&#xD;
                hypercholesterolemia, smoking)&#xD;
&#xD;
             2. blood markers of increased cardiovascular risk&#xD;
&#xD;
        3. To determine predictive associations of between CAD with outcome (endpoint definitions&#xD;
           in appendix)&#xD;
&#xD;
        4. To determine the risk-benefit ratio (number of subsequent interventions, complications,&#xD;
           radiation exposure, late onset of cancer diseases, etc).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2 year</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5 year</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults referred to clinical cardiac computertomography imaging&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (=/&gt;18 years of age)&#xD;
&#xD;
          2. Able to provide informed consent&#xD;
&#xD;
          3. Clinical indication for cardio-CT in line with the latest clinical guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. standard contraindications to CT (in line with local roles and guidelines - please see&#xD;
             Appendix)&#xD;
&#xD;
          2. known allergy to iodinated contrast agent&#xD;
&#xD;
          3. suspected acute kidney injury&#xD;
&#xD;
          4. unstable hemodynamic status or arrhythmias&#xD;
&#xD;
          5. suspected acute coronary syndrome&#xD;
&#xD;
          6. manifest thyrotoxicosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valentina O Puentmann, MD, PhD</last_name>
    <phone>004969630184491</phone>
    <email>cvi-research@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franziska Weis</last_name>
    <phone>004969630184491</phone>
    <phone_ext>84491</phone_ext>
    <email>cvi-research@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for experimental and translational cardiovascular imaging</name>
      <address>
        <city>Frankfurt Am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Puentmann, MD, PhD</last_name>
      <email>cvi-research@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Weis</last_name>
      <email>cvi-research@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Valentina Puntmann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eike Nagel, MD, PgD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Vogl, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Valentina Puentmann</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

